📰 Kodiak Sciences News
Page 4 - Kodiak Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Kodiak Sciences. Real-time updates on events, politics, business and more.
November 21, 2023
Capital One Financial upgraded shares of Kodiak Sciences (NASDAQ:KOD – Free Report) from an equal weight rating to an overweight rating in a research report released on Friday, MarketBeat reports. The firm currently has $12.00 price objective on the stock, up from their prior price objective of $7.00. A number of other brokerages have also […]
November 17, 2023
Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance.
November 16, 2023
Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) was the recipient of a significant drop in short interest in October. As of October 31st, there was short interest totalling 3,350,000 shares, a drop of 14.3% from the October 15th total of 3,910,000 shares. Approximately 6.8% of the shares of the stock are short sold. Based […]
November 10, 2023
A phase 3 trial showed that tarcocimab, a biopolymer with a vascular growth factor antibody, improved vision and anatomical markers in patients with early stage diabetic retinopathy.
November 6, 2023
Some degree of improvement in disease status in 70% of patients treated with tarcocimab
November 3, 2023
The Benzinga Stock Whisper Index uses proprietary data to look at stocks with increased interest from investors.
November 2, 2023
Kodiak Sciences Inc. announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology to be held November 3-6, 2023 in San Francisco....
October 23, 2023
The increasing diagnosed prevalence, and the development of well-designed, randomized, controlled non-crossover trials with the potential benefits for RVO patients will drive the retinal vein occlusion market growth in the forecast period (2023–2032).New York, USA, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Retinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsight The increasing diagnosed prevalence, and the development ...
October 23, 2023
New York, USA, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Retinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsight The increasing diagnosed
October 17, 2023
Lonza Group AG Key word Forecast Capital Markets Day 2023 New MidTerm Guidance 2024 – 2028 Supported by RampUp of Growth Projects 17Oct2023 0700 CETCEST Release of an ad hoc announcement pursuant to